References
- Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, et al. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transpl 2014; 20: 952-9. doi: 10.1002/lt.23897
- Joo I, Kim H, Lee JM. Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol 2015; 16: 50-68. doi: 10.3348/kjr.2015.16.1.50
- Gera S, Ettel M, Acosta-Gonzalez G, Xu R. Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol 2017; 9: 300-9. doi: 10.4254/ wjh. v9. i6.300
- Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 2013; 37: 496-505. doi: 10.1097/PAS.0b013e31827332b0
- Portolani N, Baiocchi GL, Coniglio A, Piardi T, Grazioli L, Benetti A, et al. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol 2008; 15: 1880-90. doi: 10.1245/s10434-008-9933-y
- Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol 2010; 25: 1485-92. doi: 10.1111/j.1440-1746. 2010.06430.x
- Yoon YI, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, et al. Postresection outcomes of combined hepatocellular carcinoma-cholangiocarcinoma, hepato-cellular carcinoma and intrahepatic cholangiocarcinoma. J Gastrointest Surg 2016; 20: 411-20. doi: 10.1007/s11605-015-3045-3
- Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949; 25: 647-55. PMID: 18152860
- Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol 2002; 17: 401-5. doi: 10.1046/j.1440-1746.2002.02734.x
- Zhou YM, Zhang XF, Wu LP, Sui CJ, Yang JM. Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. World J Gastroenterol 2014; 20: 12615-20. doi: 10.3748/wjg.v20.i35.12615
- Granata V, Fusco R, Filice S, Catalano O, Piccirillo M, Palaia R, et al. The current role and future prospectives of functional parameters by diffusion weighted imaging in the assessment of histologic grade of HCC. Infect Agent Cancer 2018; 13: 23. doi: 10.1186/s13027-018-0194-5
- Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, et al. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: lights and shadows. Oncotarget 2017; 8: 51224-37. doi: 10.18632/oncotarget.17227
- Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, et al. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer 2017; 12: 23. doi: 10.1186/ s13027-017-0132-y
- Granata V, Fusco R, Catalano O, Guarino B, Granata F, Tatangelo F, et al. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for hepatocellular carcinoma: correlation with histologic grade. Oncotarget 2016; 7: 79357-64. doi: 10.18632/oncotarget.12689
- Granata V, de Lutio di Castelguidone E, Fusco R, Catalano O, Piccirillo M, Palaia R, et al. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area. Radiol Med 2016; 121: 122-31. doi: 10.1007/s11547-015-0582-5.
- Zhang XY, Luo Y, Wen TF, Jiang L, Li C, Zhong XF, et al. Contrast-enhanced ultrasound: improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment. World J Gastroenterol 2014; 20: 1262836. doi: 10.3748/wjg.v20.i35.12628
- Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging 2012; 37: 215-30. doi: 10.1007/s00261-011-9794-x
- Jeon SK, Joo I, Lee DH, Lee SM, Kang HJ, Lee KB, et al. Combined hepato-cellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 2019; 29: 373-82. doi: 10.1007/s00330-018-5605-x
- The American College of Radiology. Liver Reporting & Data System (LI-RADS). [cited 2020 Jan 15]. Available at: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS
- Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503. doi: 10.1002/1097-0142(195405)7:3<;462::aid-cncr2820070308>3.0.co;2-e
- Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 2019; 29: 2408-16. doi: 10.1007/ s00330-018-5893-1
- Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ. Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepato- cellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 2016; 207: 25-31. doi: 10.2214/AJR.15.14997
- Sammon J, Fischer S, Menezes R, Hosseini-Nik H, Lewis S, Taouli B, et al. MRI features of combined hepatocellular-cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging 2018; 18: 8. doi: 10.1186/s40644-018-0142-z
- Fowler KJ, Sheybani A, Parker RA 3rd, Doherty S, M Brunt E, Chapman WC, et al. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 2013; 201: 332-9. doi: 10.2214/AJR.12.9488
- Kim JE, Kim SH, Lee SJ, Rhim H. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol 2011; 196: W758-65. doi: 10.2214/AJR.10.4394